INEXAS: A Phase 2 Randomized Trial of On-demand Inhaled Interferon Beta-1a in Severe Asthmatics.
Christopher McCraeMarita OlssonPer GustafsonAnna MalmgrenMalin AurellMalin FageråsCarla A Da SilvaAnders CavallinJonathan ParaskosKarin KarlssonCecilia WingrenPhillip MonkRichard MarsdenTim HarrisonPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2020)
Colds did not have the impact on asthma patients that was expected and, due to the low exacerbation rate, the trial was stopped early. On-demand AZD9412 treatment did not numerically reduce the number of exacerbations, but did attenuate URTI-induced worsening of mPEF. Severe asthma patients with high blood eosinophils or low serum interleukin-18 response are potential subgroups for further investigation of inhaled IFN-β1a.
Keyphrases
- chronic obstructive pulmonary disease
- cystic fibrosis
- end stage renal disease
- dendritic cells
- newly diagnosed
- ejection fraction
- clinical trial
- immune response
- lung function
- prognostic factors
- peritoneal dialysis
- early onset
- study protocol
- oxidative stress
- diabetic rats
- allergic rhinitis
- combination therapy
- patient reported
- phase ii
- air pollution
- acute respiratory distress syndrome